Featured Research

from universities, journals, and other organizations

Combined use of recommended heart failure therapies significantly boosts survival odds, study suggests

Date:
February 22, 2012
Source:
University of California - Los Angeles
Summary:
A new study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvement of up to 90 percent in the odds of survival over two years.

A UCLA-led study has found that a combination of several key guideline-recommended therapies for heart failure treatment resulted in an improvement of up to 90 percent in the odds of survival over two years.

Related Articles


The research is published Feb. 21 in the online Journal of the American Heart Association.

Heart failure, a chronic, progressive disease, affects millions of individuals and results in morbidity, the use of significant health care resources, and substantial costs.

While certain therapies are recommended for heart failure patients in the national guidelines of the American College of Cardiology and the American Heart Association, this study is the first to examine the specific incremental contribution of each of these therapies in improving survival when combined together progressively in a real-world clinical practice, the researchers said.

"We found incremental and cumulative improvement in the odds of two-year survival rates as each of these guideline-recommended therapies was implemented with patients," said the study's first author, Dr. Gregg Fonarow, UCLA's Eliot Corday Professor of Cardiovascular Medicine and Science and director of the Ahmanson-UCLA Cardiomyopathy Center at the David Geffen School of Medicine at UCLA.

Fonarow noted that the findings also provide further rationale for employing performance-improvement systems and disease-management programs to ensure the implementation of recommended therapies in eligible heart failure patients.

For the study, researchers utilized the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF), a database of patients at 167 cardiology-practice clinics across the country.

The team reviewed medical chart data from 1,376 patients who died at 24 months, compared with 2,752 controls who survived to 24 months. Researchers specifically targeted patients who had weakening function in the heart's left venticle, a symptom of chronic heart failure, which occurs when the when the entricle can no longer pump enough blood to the body's other organs.

The seven key guideline-recommended therapies evaluated were:

  • Three types of heart failure medications: beta blockers, aldosterone antagonists, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
  • Cardiac resynchronization therapy, which helps coordinate heart contractions.
  • Anti-coagulant therapy for atrial fibrillation, to prevent clot formation in patients with an irregular heart beat.
  • Implantable cardioverter-defibrillator devices, to deliver electrical shocks if potentially fatal heart-rhythm abnormalities occur.
  • Heart-failure patient education.

Researchers found that as each therapy was added, the overall survival rate increased incrementally -- starting with a 39 percent improved odds of two-year survival when just beta blockers were prescribed, and up to 81 percent to 90 percent when several other therapies were added -- compared to no treatment at all.

However, the team found that the survival benefit appeared to plateau once a patient sequentially received four to five therapies, demonstrating an 83 percent reduction in the odds of 24-month mortality.

"Together the cumulative 24-month survival benefits of these therapies are impressive," said Fonarow, co-chief of clinical cardiology in the UCLA Division of Cardiology. "High-quality, patient-centered outcomes research is a national priority and can better inform clinical decision-making. This study provides patients, clinicians, purchasers and policymakers with compelling evidence of the incremental improvements in clinical outcomes for patients with heart failure that can be achieved with guideline-recommended therapies."

Each individual therapy, with a single exception, was also associated with a survival benefit. Beta blockers and cardiac resynchronization therapy imparted the greatest individual benefits by providing lowered odds of mortality of 42 percent and 44 percent, respectively.

Fonarow also noted that being able to independently value these heart failure therapies may provide a basis for choosing between treatments when a choice needs to be made on a clinical level, based on cost, tolerance or adherence issues.   The one therapy that was not associated with improved mortality benefit was the use of aldosterone antagonists. Fonarow said that while multiple randomized clinical trials have demonstrated the benefits of aldosterone antagonist therapy in heart failure patients, more study in an outpatient setting needs to be done to evaluate the real-world clinical effectiveness of these agents.

Medtronic Inc., a manufacturer of cardiac resynchronization therapy and implantable defibrillator devices, provided financial and material support for the IMPROVE HF registry. The company had no role or input in the selection of end-points or quality measures used in the study.


Story Source:

The above story is based on materials provided by University of California - Los Angeles. The original article was written by Rachel Champeau. Note: Materials may be edited for content and length.


Journal Reference:

  1. G. C. Fonarow, N. M. Albert, A. B. Curtis, M. Gheorghiade, Y. Liu, M. R. Mehra, C. M. O'Connor, D. Reynolds, M. N. Walsh, C. W. Yancy. Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF. Journal of the American Heart Association, 2012; 1 (1): 16 DOI: 10.1161/JAHA.111.000018

Cite This Page:

University of California - Los Angeles. "Combined use of recommended heart failure therapies significantly boosts survival odds, study suggests." ScienceDaily. ScienceDaily, 22 February 2012. <www.sciencedaily.com/releases/2012/02/120222094246.htm>.
University of California - Los Angeles. (2012, February 22). Combined use of recommended heart failure therapies significantly boosts survival odds, study suggests. ScienceDaily. Retrieved November 29, 2014 from www.sciencedaily.com/releases/2012/02/120222094246.htm
University of California - Los Angeles. "Combined use of recommended heart failure therapies significantly boosts survival odds, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/02/120222094246.htm (accessed November 29, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Saturday, November 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins